JNJ

Johnson & Johnson

Jun 22 • 11:47AM ET

230.96

+2.57 1.13 %

Healthcare • Drug Manufacturers - General • USA • Mega • NYSE

Jun 18, 1:20 AMJohnson & Johnson CEO Joaquin Duato says the company has no plans to enter the obesity drugs market, instead focusing its pipeline on areas such as cancer.

Peers: LLY MRK PFE ABBV BMY AZN NVS AMGN SNY NVO

| Held by: VTI VOO IVV SPY VTV XLV VIG VYM VHT SPYM

Scroll to Statements

Index	DJIA, S&P 500	P/E	26.70	EPS (ttm)	8.65	Insider Own	0.13%	Shs Outstand	2.41B	Perf Week	-4.11%
Market Cap	555.98B	Forward P/E	18.09	EPS next Y	12.77	Insider Trans	-10.06%	Shs Float	2.40B	Perf Month	0.72%
Enterprise Value	588.92B	PEG	1.98	EPS next Q	2.85	Inst Own	77.13%	Short Float	0.97%	Perf Quarter	-1.87%
Income	21.04B	P/S	5.77	EPS this Y	7.28%	Inst Trans	0.21%	Short Ratio	2.96	Perf Half Y	9.81%
Sales	96.36B	P/B	6.85	EPS next Y	10.28%	ROA	10.66%	Short Interest	23.41M	Perf YTD	11.60%
Book/sh	33.73	P/C	25.21	EPS next 5Y	9.15%	ROE	26.42%	52W High	251.71 -8.24%	Perf Year	54.19%
Cash/sh	9.16	P/FCF	31.26	EPS past 3/5Y	17.88% 14.90%	ROIC	17.72%	52W Low	149.04 54.97%	Perf 3Y	39.45%
Dividend Est.	5.28 (2.29%)	EV/EBITDA	17.51	Sales past 3/5Y	5.56% 2.67%	Gross Margin	67.96%	Volatility	2.12% 1.88%	Perf 5Y	41.16%
Dividend TTM	5.24 (2.27%)	EV/Sales	6.11	EPS Y/Y TTM	-3.56%	Oper. Margin	26.88%	ATR (14)	4.73	Perf 10Y	98.32%
Dividend Ex-Date	May 26, 2026	Quick Ratio	0.77	Sales Y/Y TTM	7.87%	Profit Margin	21.83%	RSI (14)	48.68	Recom	1.84
Dividend Gr. 3/5Y	4.92% 5.25%	Current Ratio	1.03	EPS Q/Q	-52.82%	SMA20	-0.31%	Beta	0.25	Target Price	261.90
Payout	46.59%	Debt/Eq	0.68	Sales Q/Q	9.93%	SMA50	0.35%	Rel Volume	0.59	Prev Close	228.39
Employees	140800	LT Debt/Eq	0.46	Earnings	Jul 15 BMO	SMA200	6.93%	Avg Volume	7.91M	Price	230.96
IPO	Sep 25, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.85% 1.89%	Trades		Volume	1,790,526	Change	1.13%

Date	Action	Analyst	Rating Change	Price Target Change
May-13-26	Upgrade	Leerink Partners	Market Perform → Outperform	$265
Apr-08-26	Resumed	TD Cowen	Buy	$250
Jan-28-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$262
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$230
Oct-20-25	Upgrade	Daiwa Securities	Neutral → Outperform	$203
Oct-03-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$212
Sep-23-25	Upgrade	Guggenheim	Neutral → Buy	$206
Jul-23-25	Upgrade	Erste Group	Hold → Buy
May-13-25	Downgrade	Leerink Partners	Outperform → Market Perform	$153
Dec-10-24	Resumed	BofA Securities	Neutral	$166
Nov-15-24	Initiated	Wolfe Research	Outperform	$190
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral	$160 → $150
May-30-24	Resumed	Goldman	Neutral	$160
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy	$170
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$170 → $163
Dec-01-23	Upgrade	UBS	Neutral → Buy	$167 → $180
Oct-05-23	Initiated	RBC Capital Mkts	Outperform	$178
Sep-06-23	Initiated	HSBC Securities	Hold	$175
May-30-23	Resumed	Citigroup	Buy	$185
Mar-29-23	Initiated	UBS	Neutral	$164

Show Previous Ratings

Today 10:46AM	Merck Stocks New Drugs Were Already Answering The Big Question (Trefis)
09:08AM	Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics (Barrons.com)
08:15AM	Solvonis reports positive SVN-002 bridging data; CEO outlines next steps (Proactive)
Jun-18-26 04:57PM	What If Amgen Stock's Patent Worries Are Hiding Its Real Growth Engine? (Trefis)
11:52AM	Here's what's weighing on the Dow today (MarketWatch)
01:15AM	Loading…
01:15AM	50 Years of Dividend Hikes: These Stocks Did It (Barrons.com)
Jun-17-26 04:15PM	Nasdaq, US stocks slide as Fed forecasts possible rate hike (Yahoo Finance Video)
03:41PM	J&J Has No Plans to Enter Obesity Drugs Market, CEO Says (Bloomberg)
03:33PM	J&J Skips GLP-1 Race, Targets No. 1 Cancer Spot By 2030 (GuruFocus.com)
02:21PM	Eli Lilly Stock's Trillion-Dollar Question (Trefis)
01:08PM	The Number That Could Test Johnson & Johnson Stock (Trefis)
11:57AM	Everyone Is Watching Eli Lilly Stock's New Drugs. Here Is the Metric That Vanished (Trefis)
11:36AM	Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says (Investing.com)
Jun-16-26 12:48PM	J&J CEO says curing certain cancers within a decade is realistic (Quartz)
07:17AM	J&J commits $1B to expand contact lens production in Florida (MedTech Dive)
05:08AM	Loading…
05:08AM	Neumora depression drug fails; EnGene to cut 50% of staff (BioPharma Dive)
Jun-15-26 12:50PM	J&J outlays $1bn to strengthen Floridian contact lens manufacturing provision (Medical Device Network)
07:06AM	Factbox-Global drugmakers rush to boost US presence as tariff threat looms (Reuters)
06:00AM	Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida (Business Wire)
Jun-12-26 04:53PM	What Could Push JNJ Stock Higher From Here? (Trefis)
03:14PM	JNJ Raised the Bar: So Why Is the Stock Standing Still? (Trefis)
01:31PM	The Catch Hiding In Eli Lilly Stock's Growth Story (Trefis)
Jun-11-26 02:03PM	Why Did Wall Street Misprice JNJ Stock? (Trefis)
10:58AM	Johnson & Johnson Eyes Rare Disease Expansion (GuruFocus.com)
08:40AM	Johnson & Johnson Reports Strong Late-Stage Results for Rare Blood Disorder Therapy (JNJ) (InvestorsHub)
08:06AM	How Shockwave Medical plans to keep rivals at bay in burgeoning IVL sector (Medical Device Network)
07:45AM	Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients (Business Wire)
05:42AM	Podcast: How Shockwave Medical plans to keep rivals at bay in burgeoning IVL sector (Medical Device Network)
02:48AM	Poolbeg Pharma shows clinical progress with latest updates (Proactive)
02:03AM	IMAAVY (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies (PR Newswire)
11:22AM	Loading…
Jun-10-26 11:22AM	Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial (Business Wire)
Jun-09-26 01:29PM	All 30 Dow Jones Stocks Ranked: Buy, Sell or Hold? (Kiplinger)
06:59AM	J&J to acquire Firefly Bio for $1bn to enhance oncology pipeline (Pharmaceutical Technology)
05:47AM	J&J secures extended NICE approval for Darzalex following earlier refusal (Pharmaceutical Technology)
Jun-08-26 04:10PM	J&J Pays $1 Billion to Crack an Undruggable Cancer Target (GuruFocus.com)
03:49PM	Why Is Lilly Stock Growing Like A Silicon Valley Tech Darling? (Trefis)
09:33AM	Johnson & Johnson acquires Firefly Bio for $1 billion (Quartz)
09:07AM	Can MariTide Save Amgen Stock From Its Fading Blockbusters? (Trefis)
09:01AM	Johnson & Johnson to Buy Firefly Bio for $1 Billion (The Wall Street Journal)
08:55AM	Is AbbVie Stock The Right Defensive Pick In This Volatile Market? (Trefis)
08:00AM	Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform (Business Wire)
Jun-05-26 06:55PM	Is Amgen An Undervalued Stock Or Value Trap? (Trefis)
04:11PM	Nasdaq plunges 1,100 points over renewed rate hike concerns (Yahoo Finance Video)
12:48PM	J&J, Medtronic back CereVascs $85M funding round (MedTech Dive)
Jun-04-26 04:23PM	75% Upside For LLY Stock? (Trefis)
10:49AM	CereVasc raises $85m to advance hydrocephalus treatment (Medical Device Network)
Jun-03-26 12:04AM	Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study (PR Newswire)
12:03AM	Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjogren's disease (PR Newswire)
May-31-26 08:29AM	RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited (PR Newswire)
08:27AM	Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm (PR Newswire)
May-29-26 02:00PM	RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer (PR Newswire)
08:18AM	New TECVAYLI (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma (PR Newswire)
May-28-26 07:10PM	FDA approves label expansion, cementing TREMFYA as the only IL-23 inhibitor proven to help stop further joint damage (PR Newswire)
12:30PM	J&J's Strategy for Deals on the Cheap Faces a Big Test (The Wall Street Journal)
08:03AM	BSX Stock: Don't Try To Catch The Falling Knife (Trefis)
05:30AM	J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge? (The Wall Street Journal)
May-27-26 04:22PM	Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results (Business Wire)
07:00AM	J&Js DePuy Synthes inks deal to buy orthopedic surgery tech (MedTech Dive)
May-26-26 09:12AM	DePuy Synthes secures exclusive NOVOSIS bone graft distribution partnership (JNJ) (InvestorsHub)
07:55AM	Nasdaq leads Wall Street gains as chip and AI stocks rally (Proactive)
May-22-26 08:27AM	IBRX Says ANKTIVA Delivers Up To $314K Cost Advantage Over J&J's TAR-200 Everything To Know About ImmunityBios Findings (Stocktwits)
May-20-26 01:20PM	Can a New Arthritis Drug Make Immunovant the Next Biotech Star? (Barrons.com)
11:38AM	2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug (Barrons.com)
08:02AM	How Nanobiotix Got Wall Street's Attention By Using Physics To Battle Cancer (Investor's Business Daily)
06:50AM	Kenvue tracks packaging through recycling stream with Greyparrots AI (Packaging Dive)
May-19-26 11:52AM	Is BSX Stock A Value Trap Or A Rebound Play? (Trefis)
May-17-26 12:52PM	Health officials declare Ebola outbreak a public health emergency (MarketWatch)
May-14-26 04:01PM	Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation (PR Newswire)
May-13-26 02:09PM	Dow trims losses in afternoon trading (MarketWatch)
12:01PM	AI Drug Designer Isomorphic Details Lofty Plans for $2.1B in New Funding (The Daily Upside)
11:14AM	JNJ gets Wall Street boost as blockbuster drug bets ignite growth hopes (Investing.com)
09:35AM	AMD, Under Armour downgraded: Wall Street's top analyst calls (The Fly)
07:08AM	J&J launches improved Shockwave catheter (MedTech Dive)
May-12-26 03:14PM	S&P 500, Nasdaq under pressure as chip stocks see red (Yahoo Finance Video)
12:17PM	Google AI legend raises big money for startup targeting this cutting-edge goal (MarketWatch)
07:45AM	Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave C2 Aero Coronary IVL Catheter (Business Wire)
May-11-26 04:34PM	Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference (Business Wire)
08:00AM	Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP (PR Newswire)
May-09-26 07:30AM	Johnson & Johnson CEO: Americas innovation advantage starts with health (Fortune)
May-07-26 02:46PM	DARZALEX royalties drive Genmabs Q1 revenue higher amid expansion push (Investing.com)
11:34AM	Why This Income Pro Likes Banks, Chip-Equipment Companies, and More (Barrons.com)
08:00AM	Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission (PR Newswire)
04:52AM	Lilly, Gilead lead pharmas M&A boom (Pharma Voice)
May-06-26 09:15AM	Can Pfizer Stock Outrun A $17B Revenue Void? (Trefis)
06:30AM	Avalo shares spike on skin drug data; BioNTech to cut staff (BioPharma Dive)
03:00AM	CellCentric raises $220M for a transformative multiple myeloma medicine (BioPharma Dive)
May-05-26 12:56PM	J&Js soft tissue surgical robot succeeds in pivotal gastric bypass study (Medical Device Network)
08:05AM	Johnson & Johnson study shows TREMFYA (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease (PR Newswire)
May-04-26 04:06PM	Trump Administration Targets Dismantling of Already-Weakened DEI (Bloomberg)
08:00AM	CAPLYTA (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis (PR Newswire)
May-01-26 10:50AM	Eli Lilly Stocks Path To 30% Upside (Trefis)
Apr-30-26 08:02AM	Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations (Business Wire)
Apr-29-26 07:02PM	Microsoft says it has over 20M paid Copilot users, and they really are using it (TechCrunch)
06:09AM	American industry is winning: White House touts factory boom how investors can ride the reshoring wave (Moneywise)
Apr-28-26 11:45AM	Jim Cramer says health care is the 'cold' hedge your AI-heavy portfolio is missing and shares 4 stocks to consider (Moneywise)
11:29AM	J&J starts head-to-head PFA trial against Boston Scientific device (MedTech Dive)
10:08AM	Shares of Coca-Cola are lifting the Dow after the company beats earnings (MarketWatch)
08:08AM	Nasdaq retreats falls as OpenAI report hits Oracle, Nvidia and other AI stocks (Proactive)
02:06AM	FTSE 100 Live: BP and Shell provide boost as oil hits $110, Barclays falls on results (Proactive)
Apr-27-26 04:33PM	Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference (Business Wire)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

CEO & ChairmanMr. Joaquin Duato

Executive VP & Worldwide Chairman of Innovative MedicineMs. Jennifer L. Taubert

Ph.D.Dr. John C. Reed M.D.

Executive VP & Worldwide Chairman of MedTechMr. Timothy Schmid

Controller & Chief Accounting OfficerMr. Robert J. Decker Jr.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Jun 11 '26	Option Exercise	115.67	10,000	1,156,700	124,288	Jun 12 05:23 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Jun 11 '26	Sale	241.15	10,000	2,411,500	114,288	Jun 12 05:23 PM
Wengel Kathryn E	Officer	Jun 11 '26	Proposed Sale	240.15	10,000	2,401,539		Jun 11 01:44 PM
REED JOHN C	EVP, Innovative Medicine, R&D	May 01 '26	Option Exercise	0.00	25,255	0	35,913	May 04 04:58 PM
Decker Robert J	VP Corporate Controller	Feb 27 '26	Option Exercise	115.67	4,075	471,355	27,757	Mar 03 04:21 PM
Decker Robert J	VP Corporate Controller	Feb 27 '26	Sale	247.87	4,075	1,010,070	23,682	Mar 03 04:21 PM
Decker Robert J	Officer	Feb 27 '26	Proposed Sale	247.87	4,075	1,010,070		Feb 27 02:35 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 20 '26	Sale	245.66	1,322	324,763	25,447	Feb 23 05:20 PM
Schmid Timothy	Officer	Feb 20 '26	Proposed Sale	245.66	1,322	324,763		Feb 20 10:46 AM
Swanson James D.	EVP, CIO	Feb 13 '26	Option Exercise	132.73	51,418	6,824,543	47,211	Feb 18 09:12 PM
Swanson James D.	EVP, CIO	Feb 17 '26	Option Exercise	164.62	20,521	3,378,167	46,219	Feb 18 09:12 PM
Swanson James D.	EVP, CIO	Feb 15 '26	Option Exercise	0.00	1,201	0	26,007	Feb 18 09:12 PM
Swanson James D.	EVP, CIO	Feb 13 '26	Sale	243.73	41,559	10,129,312	25,020	Feb 18 09:12 PM
Swanson James D.	EVP, CIO	Feb 17 '26	Sale	242.70	20,521	4,980,447	25,698	Feb 18 09:12 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 15 '26	Option Exercise	0.00	1,241	0	114,613	Feb 18 09:12 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 13 '26	Option Exercise	0.00	14,357	0	120,096	Feb 18 09:12 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 15 '26	Option Exercise	0.00	994	0	20,081	Feb 18 09:12 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 13 '26	Option Exercise	0.00	4,012	0	20,286	Feb 18 09:12 PM
Wolk Joseph J	Exec VP, CFO	Feb 17 '26	Option Exercise	126.65	64,693	8,193,223	72,347	Feb 18 09:12 PM
Wolk Joseph J	Exec VP, CFO	Feb 15 '26	Option Exercise	0.00	3,849	0	39,778	Feb 18 09:12 PM
Wolk Joseph J	Exec VP, CFO	Feb 13 '26	Option Exercise	0.00	39,242	0	51,463	Feb 18 09:12 PM
Wolk Joseph J	Exec VP, CFO	Feb 17 '26	Sale	242.80	89,654	21,767,827	14,000	Feb 18 09:12 PM
Decker Robert J	VP Corporate Controller	Feb 15 '26	Option Exercise	0.00	683	0	23,777	Feb 18 09:12 PM
Decker Robert J	VP Corporate Controller	Feb 13 '26	Option Exercise	0.00	3,053	0	23,950	Feb 18 09:12 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 17 '26	Option Exercise	156.89	51,648	8,103,281	42,868	Feb 18 09:12 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 15 '26	Option Exercise	0.00	3,196	0	13,469	Feb 18 09:12 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 17 '26	Sale	243.00	53,931	13,105,233	10,658	Feb 18 09:12 PM
Forminard Elizabeth	EVP, Chief Legal Officer	Feb 15 '26	Option Exercise	0.00	2,024	0	24,112	Feb 18 09:11 PM
Forminard Elizabeth	EVP, Chief Legal Officer	Feb 13 '26	Option Exercise	0.00	14,357	0	29,591	Feb 18 09:11 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 15 '26	Option Exercise	0.00	3,441	0	195,396	Feb 18 09:11 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 13 '26	Option Exercise	0.00	28,714	0	206,318	Feb 18 09:11 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 18 '26	Option Exercise	121.17	22,623	2,741,335	40,394	Feb 18 09:11 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 15 '26	Option Exercise	0.00	2,054	0	27,217	Feb 18 09:11 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 13 '26	Option Exercise	0.00	4,877	0	26,994	Feb 18 09:11 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 18 '26	Sale	244.33	22,623	5,527,506	26,769	Feb 18 09:11 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 15 '26	Option Exercise	0.00	8,187	0	326,407	Feb 18 09:11 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 13 '26	Option Exercise	0.00	76,523	0	351,501	Feb 18 09:11 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 15 '26	Option Exercise	0.00	1,018	0	29,470	Feb 18 09:11 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 13 '26	Option Exercise	0.00	9,002	0	32,452	Feb 18 09:11 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 17 '26	Sale	243.39	6,197	1,508,288	23,003	Feb 18 09:11 PM
Schmid Timothy	Officer	Feb 18 '26	Proposed Sale	244.33	22,623	5,527,546		Feb 18 11:14 AM
Broadhurst Vanessa	Officer	Feb 17 '26	Proposed Sale	243.39	6,197	1,508,300		Feb 17 04:10 PM
Swanson James D.	Officer	Feb 17 '26	Proposed Sale	242.70	20,521	4,980,510		Feb 17 02:52 PM
Wolk Joseph J	Officer	Feb 17 '26	Proposed Sale	242.80	89,654	21,767,965		Feb 17 02:43 PM
REED JOHN C	Officer	Feb 17 '26	Proposed Sale	243.00	53,931	13,105,233		Feb 17 12:44 PM
Swanson James D.	Officer	Feb 13 '26	Proposed Sale	243.73	41,559	10,129,246		Feb 13 02:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 06 '26	Option Exercise	101.87	15,571	1,586,218	32,460	Feb 10 09:46 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 06 '26	Option Exercise	101.87	5,625	573,019	19,744	Feb 09 07:42 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 06 '26	Option Exercise	101.87	38,945	3,967,327	133,226	Feb 09 07:40 PM
Forminard Elizabeth	EVP, Chief Legal Officer	Feb 05 '26	Option Exercise	129.51	8,921	1,155,359	21,774	Feb 06 05:46 PM
Forminard Elizabeth	Officer	Feb 05 '26	Proposed Sale	237.90	6,226	1,481,195		Feb 05 04:31 PM
Duato Joaquin	CEO and Chairman of the Board	Jan 26 '26	Sale	221.23	100,000	22,122,893	30,852	Jan 28 06:07 PM
Joaquin Duato	CEO, Chariman	Jan 26 '26	Proposed Sale	220.14	100,000	22,014,000		Jan 26 04:57 PM
MORIKIS JOHN G	Director	Nov 26 '25	Buy	206.15	1,250	257,688	1,849	Dec 01 04:15 PM
JOHNSON & JOHNSON	10% Owner	Nov 26 '25	Sale	10.03	6,337	63,560	4,040,861	Dec 01 04:07 PM
JOHNSON & JOHNSON	10% Owner	Nov 24 '25	Sale	10.06	2,200	22,132	4,047,198	Nov 25 12:54 PM
JOHNSON & JOHNSON	10% Owner	Nov 21 '25	Sale	10.00	500	5,000	4,049,398	Nov 25 12:54 PM
JOHNSON & JOHNSON	10% Owner	Nov 12 '25	Sale	10.00	1,000	10,000	4,049,898	Nov 14 03:07 PM
JOHNSON & JOHNSON	10% Owner	Nov 06 '25	Sale	10.21	52,332	534,310	4,051,098	Nov 10 03:28 PM
JOHNSON & JOHNSON	10% Owner	Nov 07 '25	Sale	10.00	200	2,000	4,050,898	Nov 10 03:28 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Oct 17 '25	Option Exercise	157.92	21,721	3,430,180	32,379	Oct 20 07:13 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Oct 17 '25	Sale	192.71	21,721	4,185,793	10,658	Oct 20 07:13 PM
REED JOHN C	Officer	Oct 17 '25	Proposed Sale	192.71	21,721	4,185,794		Oct 17 10:23 AM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Sep 04 '25	Option Exercise	101.87	56,471	5,752,701	234,484	Sep 05 06:00 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Sep 04 '25	Sale	177.81	56,471	10,040,883	178,013	Sep 05 06:00 PM
Taubert Jennifer L	Officer	Sep 04 '25	Proposed Sale	177.81	56,471	10,040,904		Sep 04 02:37 PM
Forminard Elizabeth	Executive VP, General Counsel	Aug 29 '25	Option Exercise	115.67	11,521	1,332,634	22,423	Sep 03 05:13 PM
Forminard Elizabeth	Officer	Aug 29 '25	Proposed Sale	177.20	9,570	1,695,806		Aug 29 03:36 PM
Duato Joaquin	CEO and Chairman of the Board	Aug 22 '25	Option Exercise	101.87	125,824	12,817,691	401,791	Aug 25 07:12 PM
Duato Joaquin	CEO and Chairman of the Board	Aug 22 '25	Sale	179.21	125,824	22,548,655	275,967	Aug 25 07:12 PM
Duato Joaquin	Officer	Aug 22 '25	Proposed Sale	180.03	125,824	22,652,724		Aug 22 01:58 PM
Wolk Joseph J	Exec VP, CFO	Aug 15 '25	Option Exercise	101.87	16,820	1,713,453	30,820	Aug 18 06:19 PM
Wolk Joseph J	Exec VP, CFO	Aug 15 '25	Sale	176.91	16,820	2,975,571	14,000	Aug 18 06:19 PM
Wolk Joseph J	Officer	Aug 15 '25	Proposed Sale	176.91	16,820	2,975,571		Aug 15 03:57 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Jul 17 '25	Sale	163.55	19,137	3,129,830	10,658	Jul 18 04:12 PM
REED JOHN C	Officer	Jul 17 '25	Proposed Sale	163.55	19,137	3,129,831		Jul 17 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JNJ

Johnson & Johnson

Upgrade your Finviz experience